FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
This market resolves based on the FDA's approval decision for Ivonescimab by Summit Therapeutics in 2026.
Kalshi$28 traded 24hEnds Dec 31, 2026Outcomes
Yes pays $1 if it happens · best price highlighted
| Outcome | Chance | 24h | Last 24h | Kalshi |
|---|---|---|---|---|
| a full approval or an accelerated approval | 85% | — | 88¢ |
a full approval or an accelerated approval
85%
—Yes price on Kalshi, last 2 weeks
Discussion
Posts and calls about this event
Live room
Connecting…Loading…
Sign in to chat in the room.